Selank

Background

Selank (also known as TP‑7) is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin (Thr‑Lys‑Pro‑Arg), engineered by addition of three amino acids (Pro‑Gly‑Pro) to increase stability and prolong activity.[13] Selank’s sequence is typically reported as Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro.[13] It was developed in Russia at the Moscow Research Institute of Molecular Genetics and related institutions as part of a program to create peptide‐based neuromodulators with anxiolytic and nootropic properties.

Selank is classified pharmacologically as a nootropic and anxiolytic peptide.[13] Its design sought to retain tuftsin’s immunomodulatory characteristics while introducing central nervous system (CNS) activity relevant to anxiety and cognitive function.[13] Most of the published work originates from Russian laboratories, with limited dissemination in Western literature and no large, multicenter randomized controlled trials.

Preclinical studies have reported anxiolytic‑like, procognitive, and neuroprotective effects in rodent models, along with modulation of immune parameters and monoamine turnover.[13] Clinical investigations to date are predominantly small, single‑country trials in anxiety spectrum and adjustment disorders.[12][13]

Mechanism of action

Putative receptor targets and pathways

Selank does not act on a single well‑defined receptor; instead, it appears to modulate several systems, most notably GABAergic neurotransmission and immune/inflammatory signaling.

• A gene expression study in rat brain demonstrated that acute Selank administration changed the expression of multiple genes involved in GABAergic neurotransmission, including GABA receptor subunits and associated proteins, leading the authors to propose that Selank’s anxiolytic effects may converge on GABAergic pathways similarly to benzodiazepines.[15]
• The same study noted that Selank and GABA produced overlapping changes in gene expression, suggesting functional interaction or convergence at GABAergic synapses.[15]

In addition to GABAergic modulation, Selank is derived from tuftsin, which binds to tuftsin receptors on immune cells and modulates phagocytosis and cytokine release.[13] While a discrete Selank‑specific receptor has not been definitively identified, Selank retains immunomodulatory activity in vitro and in vivo, including effects on cytokine production and markers of innate immunity.[13]

Neurochemical and neurotrophic effects

Preclinical reports (largely summarized in Russian‑language reviews) indicate that Selank can:

• Influence monoamine metabolism, including serotonin and dopamine turnover, in rodent brain regions associated with emotion and cognition.[13]
• Modulate brain‑derived neurotrophic factor (BDNF) expression and other neurotrophic markers in some models, potentially contributing to nootropic effects.[13]

These findings are indirect and often based on mRNA or protein expression changes rather than receptor binding assays. The precise binding partners and downstream signaling cascades remain insufficiently characterized in the international literature.

Pharmacokinetics and delivery

Selank is typically administered intranasally, allowing bypass of extensive first‑pass metabolism and facilitating CNS exposure via nasal–brain pathways.[13] Detailed human pharmacokinetic parameters (Cmax, half‑life, CSF penetration) are not well characterized in English‑language sources; available data suggest a relatively short plasma half‑life but prolonged functional effects, consistent with peptide neuromodulators.[13]

Evidence summary

Preclinical evidence

A review focused on synthetic regulatory peptides highlights Selank as a second‑generation peptide drug with anxiolytic and nootropic actions in multiple animal models.[13] Reported findings include:

• Anxiolytic‑like activity in standard rodent tests (elevated plus maze, open field), with behavioral effects comparable in magnitude to low doses of benzodiazepines but without sedation or muscle relaxation in those models.[13]
• Cognitive enhancement in models of learning and memory, including improved performance in passive avoidance and maze tasks, particularly under stress or experimental amnesia.[13]
• Stress‑protective effects, with attenuation of stress‑induced behavioral changes and modulation of stress hormone responses.[13]

A focused study on gene expression reported that Selank administration in rats altered the expression of 45 out of 84 genes related to GABAergic neurotransmission, including GABRA2, GABRB1, and GABRG2, supporting the hypothesis of GABAergic modulation.[15] This study used brain tissue from adult Wistar rats and quantitative PCR arrays to assess transcriptional changes following a single Selank injection.[15]

Clinical evidence

Human data remain limited in sample size and geographic scope.

• Adjustment disorder study (e‑Med Journal) – In an open comparative study evaluating Selank in patients with adjustment disorder (AD), Selank administration over 2 weeks was associated with significantly greater reductions in Patient Health Questionnaire (PHQ) scores compared with a control group.[12] The report notes improvements in somatic symptoms (mean 1.2 vs 3.6), nutritional problems (0.1 vs 3.4), and alcohol misuse (0.3 vs 1.5), all with p < 0.05.[12] The total sample size and detailed randomization/blinding methodology are not clearly described in the English abstract, limiting assessment of internal validity.
• The synthetic regulatory peptides review summarizes several small Russian clinical studies in generalized anxiety, neurasthenia, and asthenic conditions, reporting that Selank produced anxiolytic effects comparable to benzodiazepines with fewer sedative side effects.[13] However, many of these trials are described in brief, with limited methodological detail and often without registration in major international trial registries.

No large, double‑blind, placebo‑controlled, multicenter trials in anxiety disorders, depression, or cognitive impairment were identified in major English‑language databases. There is also no robust published evidence for disease‑modifying effects in neurodegenerative conditions.

Clinical and research uses

Approved or routine uses (Russia and some CIS countries)

According to regional literature, Selank has been developed and used in Russia as a prescription peptide anxiolytic/nootropic for:

• Anxiety spectrum disorders, including generalized anxiety and mixed anxiety‑depressive states.[13]
• Adjustment disorders and stress‑related conditions.[12][13]
• Asthenic and neurotic conditions, and for augmentation of cognitive performance under stress in some clinical contexts.[13]

These uses are largely based on small clinical trials and extensive local clinical experience rather than large international trials.

Off‑label and investigational applications

Research and clinical reports propose potential roles for Selank in:

• Cognitive impairment and subclinical cognitive decline, based on preclinical procognitive effects and small human series.[13]
• Stress‑related alcohol misuse and somatic symptoms in adjustment disorder, as suggested by the improvement in PHQ alcohol and somatic subscales in one study.[12]
• Immune modulation, leveraging its tuftsin‑derived properties, although clinical immune endpoints remain sparsely documented.[13]

These applications should be considered investigational due to limited and regionally confined evidence.

Dosing context

The following information reflects reported regimens in the literature and does not constitute prescribing advice.

• The regulatory peptide review describes Selank as formulated primarily for intranasal administration, with clinical doses typically in the microgram range per dose, administered multiple times daily over 10–14 days.[13]
• In the adjustment disorder study, Selank was administered intranasally for 2 weeks; the English‑language report does not specify exact milligram or microgram quantities, but refers to standard clinical dosing used in Russian practice.[12]

Because published English‑language sources often omit exact numeric dosing and detailed pharmacokinetics, dose–response relationships and optimal treatment durations remain insufficiently characterized in the international literature.

Safety profile

Adverse effects

The available literature suggests a favorable short‑term tolerability profile, although systematic safety characterization is incomplete.

• The review on synthetic peptides notes that Selank and related agents were designed to minimize typical side effects of benzodiazepines, such as sedation, muscle relaxation, and dependence, and that clinical experience has not revealed major toxicity at therapeutic doses.[13]
• In the adjustment disorder study, selank treatment over 2 weeks was reported as well tolerated, with no serious adverse events mentioned in the available text.[12]

Reported or theorized adverse effects (primarily from regional experience and review summaries) include:

• Mild nasal irritation or discomfort with intranasal administration.[13]
• Occasional headache or transient dizziness.[13]

Long‑term safety data, including risks of tolerance, dependence, or withdrawal phenomena, are not well documented in peer‑reviewed English‑language sources.

Contraindications and precautions

Formal, internationally harmonized contraindication lists are not available in major regulatory documents. Based on regional labeling and peptide pharmacology, typical cautions include:[13]

• Hypersensitivity to Selank or excipients.
• Use in pregnancy and lactation only with caution, due to absence of controlled studies in these populations.
• Limited data in children; pediatric use is generally considered investigational outside local practice frameworks.

There is no clear evidence of clinically significant pharmacokinetic drug–drug interactions, but systematic interaction studies have not been published.

Regulatory status

United States

Selank is not approved by the U.S. Food and Drug Administration (FDA) as a drug for any indication.

A search of FDA databases and major trial registries does not identify Selank as an approved new drug, biologic, or orphan product.[13] It does not appear in FDA drug labels or guidance documents.

In the U.S., Selank is generally encountered, if at all, as an unapproved research chemical or compounded peptide, and any therapeutic use would be off‑label and outside regulatory approval frameworks.

European Union

Selank is also not authorized as a medicinal product by the European Medicines Agency (EMA) for use in EU member states. It does not appear in EMA’s list of centrally authorized medicines or assessment reports.[13]

Russian Federation and regional context

Selank has been developed and used as a registered medicinal product in Russia and some neighboring countries, classified as an anxiolytic/neuromodulatory peptide, typically available by prescription for anxiety and related conditions.[13] Regulatory evaluation and post‑marketing surveillance data are largely available only in Russian and are not fully integrated into EMA/FDA systems.

From the standpoint of U.S. and EU regulators, Selank remains an unapproved investigational peptide with limited, regionally concentrated clinical evidence and no formal recognition as a standard therapy.